NYSEHealth CareMedical DevicesSnapshot 2026-07-23
Reading HAE? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on steady revenue growth. The current thesis state is stable, supported by robust earnings quality and a favorable sector backdrop.
The market appears to have a neutral valuation, with expectations slightly below peer performance. There is a low fragility tier, indicating that current pricing does not reflect significant risks.
Management aims to expand organic revenue by 3-6% for fiscal 2027, showing progress with recent revenue growth. However, challenges remain in achieving operating margin expansion and maintaining free cash flow conversion.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. Positive earnings from these companies could support HAE, while any misses could pose risks to its growth trajectory.
Overall, HAE's fundamentals are strong, but the company faces risks from sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that the company's financial performance remains strong. There are no new threats identified that could weaken this positive outlook.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This growth range is a key target for Haemonetics. Meeting it shows strong business momentum.
Confirms:Organic revenue growth reported between 3% and 6% for Q1 fiscal 2027.
Disproves:Organic revenue growth reported below 3% for Q1 fiscal 2027.
Why it matters: This call will provide insights on performance and guidance. Key metrics will be discussed.
Confirms one read:Management shares good news and guidance during the earnings call.
Confirms the other:Management gives bad news or shares poor results during the earnings call.
Why it matters: Confirming the 3-6% growth target shows strong business progress. This affects investor trust.
Confirms:Fiscal 2027 organic revenue growth reported within the 3-6% range.
Disproves:Organic revenue growth is below 3% for fiscal 2027.
Why it matters: The next earnings report will show the company's financial health and growth path.
Confirms one read:Earnings per share reported above $1.29.
Confirms the other:Earnings per share reported below $1.00.
Why it matters: A drop in revenue growth would signal weakening demand in a growing sector.
Confirms:Q4 revenue growth reported below 5% year over year.
Disproves:Q4 revenue growth stays above 5% year over year.
Why it matters: Stable leaders help guide the company. Changes can affect how investors feel and plan.
Confirms:A new executive hire was announced. This will make the leadership stronger.
Disproves:More executives are leaving. There are also issues with leadership.
Why it matters: This margin expansion is important for profitability. It shows how well the company is managing costs.
Confirms:Operating margin expands by 75 bps or more YoY.
Disproves:Operating margin expands less than 50 bps YoY.
Why it matters: A drop in sector revenue growth may show bigger problems for Haemonetics.
Confirms:Sector revenue growth reported below its median year over year.
Disproves:Sector revenue growth remains above its median year over year.
Why it matters: Higher margins help profits over time. They show how well the management runs the company.
Confirms:Adjusted operating margin rises by at least 50 basis points from last year.
Disproves:Adjusted operating margin falls or stays the same compared to last year.
Why it matters: Maintaining ~80% free cash flow conversion is crucial for financial health. It impacts capital allocation.
Confirms:Free cash flow conversion reported at or above 80%.
Disproves:Free cash flow conversion reported below 70%.
